Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2013-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3451
- Registration Number
- NCT00112918
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-05-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 218
- Registration Number
- NCT00111631
A Study to Assess Beta-Lactam in the Treatment of Hospitalized Patients With Bacterial Pneumonia
- First Posted Date
- 2005-05-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 302
- Registration Number
- NCT00111644
A Study of DPP-IV Inhibitor in Patients With Type 2 Diabetes
- First Posted Date
- 2005-05-25
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 291
- Registration Number
- NCT00111670
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-04-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 673
- Registration Number
- NCT00109408
Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-04-07
- Last Posted Date
- 2016-06-21
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 569
- Registration Number
- NCT00107653
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 499
- Registration Number
- NCT00106522
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 623
- Registration Number
- NCT00106548
A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1220
- Registration Number
- NCT00106574
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-03-28
- Last Posted Date
- 2014-02-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1196
- Registration Number
- NCT00106535
© Copyright 2024. All Rights Reserved by MedPath